The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Switzerland has so far been spared tariff threats from the new US President Donald Trump. Nevertheless, Swiss companies are taking precautions.

The Wasatch Global Value Fund—Investor Class returned -5.78% in the fourth quarter of 2024, underperforming the MSCI AC (All ...

The Asia-Pacific nuclear medicine market was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028. The market is ...

Interested in blogging for timesofindia.com? We will be happy to have you on board as a blogger, if you have the knack for writing. Just drop in a mail at [email protected] with a brief ...